Published in Circ Res on March 01, 2007
A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell (2008) 6.16
Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res (2012) 3.02
NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A (2010) 2.36
NOX enzymes as novel targets for drug development. Semin Immunopathol (2008) 1.90
Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med (2011) 1.74
CaMKII in the cardiovascular system: sensing redox states. Physiol Rev (2011) 1.67
Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation (2010) 1.54
Contractile Function During Angiotensin-II Activation: Increased Nox2 Activity Modulates Cardiac Calcium Handling via Phospholamban Phosphorylation. J Am Coll Cardiol (2015) 1.47
Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol (2012) 1.46
Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol (2011) 1.44
Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. Redox Biol (2014) 1.37
NADPH oxidases in heart failure: poachers or gamekeepers? Antioxid Redox Signal (2012) 1.27
Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol (2010) 1.25
NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies. Basic Res Cardiol (2011) 1.23
Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med (2011) 1.22
Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes (2010) 1.20
Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol (2015) 1.19
Redox signaling in cardiovascular health and disease. Free Radic Biol Med (2013) 1.16
Redox modification of cell signaling in the cardiovascular system. J Mol Cell Cardiol (2011) 1.15
NADPH oxidases and cardiac remodelling. Heart Fail Rev (2011) 1.14
Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal (2012) 1.10
Direct Antioxidant Properties of Bilirubin and Biliverdin. Is there a Role for Biliverdin Reductase? Front Pharmacol (2012) 1.03
Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol (2011) 1.02
Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc Res (2011) 1.01
Cardiac oxidative stress and remodeling following infarction: role of NADPH oxidase. Cardiovasc Pathol (2008) 1.01
Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. Am J Physiol Heart Circ Physiol (2012) 1.00
Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol (2008) 0.99
ROS and RNS signaling in heart disorders: could antioxidant treatment be successful? Oxid Med Cell Longev (2011) 0.99
Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol (2009) 0.94
Myocardial infarction causes inflammation and leukocyte recruitment at remote sites in the myocardium and in the renal glomerulus. Inflamm Res (2013) 0.94
Pathway-based genome-wide association analysis of coronary heart disease identifies biologically important gene sets. Eur J Hum Genet (2012) 0.93
Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction. PLoS One (2013) 0.92
NADPH oxidase and cardiac failure. J Cardiovasc Transl Res (2010) 0.91
Myocardial infarction in mice alters sarcomeric function via post-translational protein modification. Mol Cell Biochem (2011) 0.91
Which NADPH oxidase isoform is relevant for ischemic stroke? The case for nox 2. Antioxid Redox Signal (2012) 0.91
MnSOD protects against COX1-mediated endothelial dysfunction in chronic heart failure. Am J Physiol Heart Circ Physiol (2010) 0.90
The presence of p47phox in liver parenchymal cells is a key mediator in the pathogenesis of alcoholic liver steatosis. Alcohol Clin Exp Res (2012) 0.90
Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in mice. PLoS One (2014) 0.89
Low-density lipoprotein receptor gene transfer in hypercholesterolemic mice improves cardiac function after myocardial infarction. Gene Ther (2011) 0.87
Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation. Kidney Int (2012) 0.86
Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens (2011) 0.86
LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse. Gene Ther (2011) 0.85
Current status of NADPH oxidase research in cardiovascular pharmacology. Vasc Health Risk Manag (2013) 0.85
NAD(P)H oxidase subunit p47phox is elevated, and p47phox knockout prevents diaphragm contractile dysfunction in heart failure. Am J Physiol Lung Cell Mol Physiol (2015) 0.81
Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction. J Mol Cell Cardiol (2016) 0.81
Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation. Front Physiol (2012) 0.79
NADPH oxidase-2 inhibition restores contractility and intracellular calcium handling and reduces arrhythmogenicity in dystrophic cardiomyopathy. Am J Physiol Heart Circ Physiol (2014) 0.79
Undersized Mitral Annuloplasty Increases Strain in the Proximal Lateral Left Ventricular Wall. Ann Thorac Surg (2016) 0.79
Allopurinol and global left myocardial function in heart failure patients. J Cardiovasc Dis Res (2010) 0.79
Retracted Airway smooth muscle relaxation is impaired in mice lacking the p47phox subunit of NAD(P)H oxidase. Am J Physiol Lung Cell Mol Physiol (2007) 0.79
Increase in Levels of BDNF is Associated with Inflammation and Oxidative Stress during Cardiopulmonary Bypass. Int J Biomed Sci (2008) 0.78
P47phox-/- mice are compromised in expansion and activation of CD8+ T cells and susceptible to Trypanosoma cruzi infection. PLoS Pathog (2014) 0.78
p21-Activated kinase1 (Pak1) is a negative regulator of NADPH-oxidase 2 in ventricular myocytes. J Mol Cell Cardiol (2013) 0.77
Effects of glucose-6-phosphate dehydrogenase deficiency on the metabolic and cardiac responses to obesogenic or high-fructose diets. Am J Physiol Endocrinol Metab (2012) 0.77
Oxidative-Nitrosative Stress and Myocardial Dysfunctions in Sepsis: Evidence from the Literature and Postmortem Observations. Mediators Inflamm (2016) 0.76
Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology. Oxid Med Cell Longev (2016) 0.75
Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs. BMC Cardiovasc Disord (2017) 0.75
Arjunolic acid ameliorates reactive oxygen species via inhibition of p47(phox)-serine phosphorylation and mitochondrial dysfunction. Int J Biochem Cell Biol (2015) 0.75
Redox regulation of ischemic limb neovascularization - What we have learned from animal studies. Redox Biol (2017) 0.75
Luteolin-7-diglucuronide attenuates isoproterenol-induced myocardial injury and fibrosis in mice. Acta Pharmacol Sin (2017) 0.75
Atorvastatin blocks increased l-type Ca2+ current and cell injury elicited by angiotensin II via inhibiting oxide stress. Acta Biochim Biophys Sin (Shanghai) (2016) 0.75
Responses to Reductive Stress in the Cardiovascular System. Free Radic Biol Med (2016) 0.75
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet (2004) 9.35
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 8.17
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest (2003) 6.30
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation (2006) 5.99
A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell (2007) 5.85
Phanerozoic trends in the global diversity of marine invertebrates. Science (2008) 5.36
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med (2009) 4.52
Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med (2003) 4.46
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med (2008) 4.33
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood (2011) 4.21
Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation (2005) 4.20
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. J Infect Dis (2008) 3.84
Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med (2010) 3.83
Role of oxidative stress in atherosclerosis. Am J Cardiol (2003) 3.66
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension (2002) 3.23
Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol (2009) 3.13
JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 3.07
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood (2009) 3.00
Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet (2004) 2.90
Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med (2012) 2.87
The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res (2006) 2.85
Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med (2007) 2.85
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2013) 2.82
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Clinical applications of stem cells for the heart. Circ Res (2005) 2.78
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
Endothelial function: a critical determinant in atherosclerosis? Circulation (2004) 2.71
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol (2009) 2.58
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation (2010) 2.45
Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res (2004) 2.45
Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med (2012) 2.44
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc (2009) 2.34
Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) (2010) 2.33
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) (2010) 2.26
The hyper-IgE syndromes. Immunol Allergy Clin North Am (2008) 2.19
X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med (2006) 2.18
A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity (2011) 2.15
Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation (2013) 2.11
Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem (2003) 2.09
Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med (2012) 2.08
Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev (2005) 2.07
Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol (2005) 2.03
Nocardia veterana as a pathogen in North American patients. J Clin Microbiol (2003) 2.03
Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr (2004) 2.01
Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet (2005) 1.99
Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol (2007) 1.97
Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med (2014) 1.94
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood (2013) 1.93
Hyper-IgE syndromes. Immunol Rev (2005) 1.92
Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg Infect Dis (2009) 1.91
Inborn errors of human JAKs and STATs. Immunity (2012) 1.90
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica (2011) 1.89
Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol (2010) 1.88
Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A (2002) 1.88
Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation (2002) 1.87
Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon. Circ Res (2005) 1.86